FDA approves Myrbetriq for use in children with neurogenic detrusor overactivity
Study raises questions over coaches’ awareness of concussion protocols in youth football
29 March 2021COVID origins report: the four theories in play
29 March 2021FDA approves Myrbetriq for use in children with neurogenic detrusor overactivity
Myrbetriq (mirabegron extended-release tablets) is now approved for treatment of neurogenic detrusor overactivity, common in patients with spina bifida, in children 3 years and older, the U.S. Food and Drug Administration announced yesterday.
